Clinical data | |
---|---|
Trade names | Panzalone, Formula 405 |
Other names | Pregnenolone hemisuccinate; Pregn-5-en-3β-ol-20-one 3β-(hydrogen succinate) |
Routes of administration | Topical |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.022.728 |
Chemical and physical data | |
Formula | C25H36O5 |
Molar mass | 416.558 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Pregnenolone succinate (USANTooltip United States Adopted Name; brand names Panzalone, Formula 405; also known as pregnenolone hemisuccinate or pregn-5-en-3β-ol-20-one 3β-(hydrogen succinate)) is a synthetic pregnane steroid and an ester of pregnenolone which is described as a glucocorticoid and anti-inflammatory drug and has been patented and marketed as a topical medication in the form of a cream for the treatment of allergic, pruritic, and inflammatory dermatitis. It has also been described as a non-hormonal sterol, having neurosteroid activity, and forming a progesterone analogue via dehydrogenation.
In addition to its glucocorticoid effects, pregnenolone succinate has been found to act as a negative allosteric modulator of the GABAA receptor and a positive allosteric modulator of the NMDA receptor similarly to pregnenolone sulfate.
See also
References
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 666–. ISBN 978-1-4757-2085-3.
- Negwer M, Scharnow HG (4 October 2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 2649. ISBN 978-3-527-30247-5.
3β-Hydroxypregn-5-en-20-one hydrogen succinate = (3β)-3-(3-Carboxy-1-oxo-propoxy)pregn-5-en-20-one. S: Formula 405. Panzalone. Pregnenolone succinate. U: Glucocorticoid (anti-inflammatory, anti-allergic).
- De Navarre MG (1988). The chemistry and manufacture of cosmetics. Van Nostrand. p. 631. ISBN 9780931710162.
Pregnenolone hemisuccinate has been patented for topical use in alleviating allergic, pruritic and inflammatory dermatitis (29).
- Milne GW (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 1408–. ISBN 978-1-351-78989-9.
- Gibbs TT, Farb DH (27 October 2003). "Direct Modulation of Amino Acid Receptors by Neuroactive Steroids: Physiological and Pharmacological Implications". In Smith SS (ed.). Neurosteroid Effects in the Central Nervous System: The Role of the GABA-A Receptor. CRC Press. pp. 344, 356. ISBN 978-0-203-50816-9.
- Irwin RP, Lin SZ, Rogawski MA, Purdy RH, Paul SM (November 1994). "Steroid potentiation and inhibition of N-methyl-D-aspartate receptor-mediated intracellular Ca++ responses: structure-activity studies". The Journal of Pharmacology and Experimental Therapeutics. 271 (2): 677–682. PMID 7965782.
- Yaghoubi N, Malayev A, Russek SJ, Gibbs TT, Farb DH (August 1998). "Neurosteroid modulation of recombinant ionotropic glutamate receptors". Brain Research. 803 (1–2): 153–160. doi:10.1016/s0006-8993(98)00644-1. PMID 9729352. S2CID 41180982.
- Shirakawa H, Katsuki H, Kume T, Kaneko S, Ito J, Akaike A (November 2002). "Regulation of N-methyl-D-aspartate cytotoxicity by neuroactive steroids in rat cortical neurons". European Journal of Pharmacology. 454 (2–3): 165–175. doi:10.1016/s0014-2999(02)02493-7. PMID 12421643.
Glucocorticoids and antiglucocorticoids (D07, H02) | |
---|---|
Glucocorticoids | |
Antiglucocorticoids |
|
Synthesis modifiers | |
|
GABA receptor modulators | |||||
---|---|---|---|---|---|
Ionotropic |
| ||||
Metabotropic |
| ||||
Glutamate receptor modulators | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
This article about a steroid is a stub. You can help Misplaced Pages by expanding it. |